Prevention of invasive breast cancer in women with ductal carcinoma in situ: An update of the National Surgical Adjuvant Breast and Bowel Project experience☆
References (50)
Effect of anti-oestrogens on initiation of mammary cancer in the female rat
Eur J Cancer
(1971)Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata
Eur J Cancer
(1976)- et al.
Evaluation of the antitumour activity of the nonsteroidal antioestrogen monohydroxytamoxifen in the DMBA-induced rat mammary carcinoma model
Eur J Cancer
(1980) - et al.
Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Bteast and Bowel Project B-24 randomised controlled trial
Lancet
(1999) - et al.
Radiotherapy in breast-conserving treatment for ductal carcinoma in situ: First results of the EORTC randomised phase III trial 10853
Lancet
(2000) Current concepts in the detection and treatment of the earliest of the early breast cancers
Cancer
(1970)- et al.
Intraductal carcinoma. Long-term follow-up after treatment by biopsy alone
JAMA
(1978) - et al.
Intraductal carcinoma of the breast: Follow-up after biopsy only
Cancer
(1982) - et al.
Carcinoma in situ of the breast
Cancer
(1977) - et al.
Clinical significance of pre-invasive breast carcinoma
Cancer
(1980)
Duct carcinoma in situ
Cancer
(1982)
Five-year results of a randomized clinical trial comparing total mastectomy and segmental mastectomy with or without radiation in the treatment of breast cancer
N Engl J Med
(1985)
Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer
N Engl J Med
(1993)
Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel project B-17
J Clin Oncol
(1998)
Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) Protocol B-17: Intraductal carcinoma (duct carcinoma in situ)
Cancer
(1995)
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
J Natl Cancer Inst
(1996)
Adjuvant tamoxifen in the management of operable breast cancer: The Scottish Trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh
Lancet
(1987)
A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptorpositive tumors
N Engl J Med
(1989)
Cyclophosphamide and tamoxifen as adjuvant therapies in the management of breast cancer
Br J Cancer
(1988)
Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy
J Natl Cancer Inst
(1991)
New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a preventive agent
J Natl Cancer Inst
(1991)
Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
J Natl Cancer Inst
(1998)
Lumpectomy and axillary dissection for breast cancer: Surgical, pathological, and radiation considerations
World J Surg
(1985)
Nonparametric estimation from incomplete observations
J Am Stat Assoc
(1958)
Evaluation of survival data and two new rank order statistics arising in its consideration
Cancer Chemother Rep
(1966)
Cited by (477)
Advances and controversies in management of breast ductal carcinoma in situ (DCIS)
2022, European Journal of Surgical OncologySurgical Treatments for Ductal Carcinoma In Situ (DCIS) in Elderly Patients
2023, Anticancer Research
- ☆
Supported by Public Health Service Grants No. U10-CA-12027, U10-CA-69651, U10-CA-37377, and U10-CA-69974 from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
Copyright © 2001 Published by Elsevier Inc.